Blood Screening Market Size, Share, Growth, and Industry Analysis, By Type (Reagent & Instrument), By Application (Blood Bank & Hospital), Regional Insights and Forecast From 2026 To 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

BLOOD SCREENING MARKET REPORT OVERVIEW

The global blood screening market size is estimated at USD 3.39 Billion in 2026 and expected to rise to USD 6.4 Billion by 2035, experiencing a CAGR of 7.4% during the forecast from 2026 to 2035.

Blood screening is a very crucial procedure in contemporary medicine that is used to screen the donated blood against infectious diseases and certain disease markers before it is transfused to an individual. The main aim of it is to provide protection and purity of the blood supply with minimal chances of spreading the diseases, including HIV, Hepatitis B, Hepatitis C, West Nile Virus, and Syphilis, among others. This procedure entails the use of very delicate laboratory methods, usually Nucleic Acid Testing (NAT) and immunoassays, to identify the genetic material or antibodies of these pathogens, thus safeguarding the donor as well as the recipient of the blood product.

COVID-19 IMPACT

Market Growth REstrained by Pandemic due to Decline in the Number of Donated Blood

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market's growth and demand returning to pre-pandemic levels.

The first and the most essential impact of COVID-19 on this market was the complete decline in the number of donated blood since the lockdown, as social distancing and fear of getting infected in the collection centers caused the cancellation of the important blood drives and reduced the number of people who came to the collections in considerable amounts. This squeeze in the raw material (donated blood) had a direct impact on the volume of transactions in the screening product, such as reagents and kits, and both complicated the inventory control by blood banks and increased the rate at which old components are discarded, and also made it difficult to predict the demand to maintain the supply chain of screening technology.

LATEST TRENDS

High Rate of Technological Uptake to Propel Market Growth

A high rate of technological uptake is currently being experienced in this market, dominated by the finding of Nucleic Acid Amplification Tests (NAT) as highly sensitive and early detectors of transfusion-transmissible diseases such as HIV and hepatitis, and an emerging velocity of research attention on Next-Generation Sequencing (NGS) to conduct comprehensive, multiplex pathogen and extended blood-group antigen screening. One of the main directions is the push towards complete automation of blood processing and screening procedures to remove human factors, speed up processes, and, in many cases, integrate Artificial Intelligence (AI) and Machine Learning into predictive analytics and inventory management and increase diagnostic accuracy.

•   
•   
  

  Download Free Sample to learn more about this report

    

BLOOD SCREENING MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Reagent & Instrument

• Reagents: The reagents and kit components of this market revenue are usually the biggest portion of the total revenue, often over 50 per cent or more, because the consumables have large volume sales and are recurrent. Such items are mandatory in any blood screening and blood group typing done on donor and recipient samples.

• Instruments: The instruments segment will have a high Compound Annual Growth Rate (CAGR) owing to their high initial cost coupled with a longer life cycle than that of reagents. The global trend towards automation in the laboratory contributes to the growth to a large extent.

By Application

Based on application the market can be categorized into Blood Bank & Hospital

• Blood Banks: generally, the highest revenue and the large number of tests the bank does, a majority of the market share in most cases. They are mainly used regarding the obligatory and thorough screening of all donated blood units for Transfusion-Transmissible Infections (TTIs) such as HIV, Hepatitis B/C and Syphilis, blood grouping and compatibility testing.

• Hospital: form a large end-user market (e.g., having a substantial portion of the blood bank market and this market, occasionally described as dominating the end-user market in the larger blood bank market at approximately 55.3% of the revenue). Its primary use in hospitals is dedicated towards patient-side testing and transfusion management, such as cross-matching, blood group validation and antibody screening prior to transfusion.

MARKET DYNAMICS

Driving Factors

Swelling Mass of Blood Transfusion and Donations to Drive the Market Advancement

One of the major driving factors of the Blood Screening Market Growth because of the Swelling Mass of Blood Transfusion and Donations. This is a market that is inherently associated with the fact that the demand for blood and blood products is increasing all the time, creating the necessity to screen more blood donations than ever before. This demand increase is the direct effect of various key trends in the healthcare sector, such as the ageing of the world population susceptible to chronic diseases, the increased number of complex surgical operations (cardiovascular and transplant operations), and the high rates of road accidents and trauma treatment across the globe.

Risk of Transfusion-Transmissible Infection to Expand the Market

A second driver is the unrelenting health imperative to counter the transmission of infectious diseases through blood transfusion, which is imposed by stringent governmental regulations. All over the world, regulatory authorities have put in place mandatory screening schemes on major TTIs such as HIV, Hepatitis B (HBV), Hepatitis C (HCV) and Syphilis. New challenges (e.g., the Zika virus) or the development of the already known ones also require constant revision of screening panels and technologies.

Restraining Factor

Low- and Middle-Income Markets to the Market Growth

The only significant limiting factor to this market in the low- and middle-income markets is the initial and repeated high costs of sophisticated screening technologies and the inadequate infrastructure needed to accept them. Advanced techniques such as Nucleic Acid Testing (NAT), necessary to identify the viruses within the important time window of infection (that is, the window period), demand high upfront costs of automated tools, specialized and costly reagents, special laboratory support (temperature and constant power supply), and special technical expertise. These financial and infrastructural constraints lead to the blood banks and hospitals in resource-limited settings either not adopting or not fully implementing the most sensitive screening processes, which in most cases causes them to use older, less sensitive, and less expensive serology screening tests; thus, the quality and safety of the blood supply suffers.

High-Throughput Molecular Diagnostics to the Market Growth

Opportunity

The one major opportunity driver of such a market is unending technological progress, especially the integration of high-throughput molecular diagnostics and automation that has great potential to widen the horizons of screening.

Advanced Nucleic Acid Testing (NAT), Next-Generation Sequencing (NGS) and automated systems are enabling screening of an increasingly diverse range of new and current transfusion-transmissible infections (TTIs) more quickly, more precisely and more sensitively (lessening the critical window period).

Expense and Complications to Challenge the Market Growth

Challenge

The main difficult aspect in this market is that it is expensive and complicated to integrate advanced screening technology like Nucleic Acid Testing (NAT) and Next-Generation Sequencing (NGS), especially in low- and middle-income nations.

These advanced systems and their related proprietary reagents have high initial capital costs and maintenance costs, which limits their use by several blood banks continuing to use less sensitive screening technologies such as manual ELISA. This technological gap poses a major health problem in the world, given that many areas will not be able to adequately detect infectious diseases within the so-called window period and always provide a supply of safe blood.

•   
•   
  Download Free Sample to learn more about this report

    

BLOOD SCREENINGR MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

• North America

North America has emerged as the most dominant region in the Blood Screening Market share because its healthcare systems are highly developed, and the amount of healthcare expenditure is high in the area, which allows the advanced screening technologies to be widely adopted early. It is a significant innovation hub, which has pushed the creation and implementation of more advanced technologies such as Nucleic Acid Amplification Testing (NAT) and Next-Generation Sequencing (NGS) to promote blood safety and faster identification of Transfusion-Transmissible Infections (TTIs). High and mandatory screening standards of donated blood in the U.S. due to the existence of strong regulatory agencies such as the FDA assure the patients of safety and therefore continuously create high-quality screening product demand. The quantity of blood donations and transfusions is also rather high, and this fact means that the demand on screening reagents and instruments remains stable on an annual basis.

• Europe

There is a significant market share of Europe in this world market that is second only to the North American region and is defined by the strong regulatory focus and mature market. The European Union has introduced harmony and compulsory standards of blood tests against infections such as HIV, Hepatitis B and C (HBV, HCV) and other viruses among member states, which has provided an ultra-high standard of a market demand. The healthcare systems of the region focus on preventive care and early detection of diseases, which makes the general results of blood screening as a diagnostic tool and preventive health programmes more commonly adopted. Europe, much like North America, demonstrates having high rates of adoption of sophisticated technologies, with such nations as Germany and the U.K. frequently being at the forefront of the introduction of high-throughput automated platforms and sophisticated molecular diagnostics. The ageing population increases the demand for surgical operations and treatment of chronic diseases, which consequently increases the need for safe blood transfusions and, therefore, strict screening.

• Asia

The Asia-Pacific (Asia) market is expected to be this fastest-growing market, thus making it one of the future sources of growth. The industry is experiencing growth due to rising affordability levels for patients, rising awareness regarding the safety of blood and concerted efforts by major players in the industry to tap into the emerging economies such as China and India. Crowded population and a rising incidence of infectious diseases, coupled with soaring demand for blood and blood parts with the rising access to health care services, stipulate the need to enlarge screening. Government and private investment in the construction and updating of hospitals, blood banks, and diagnostic laboratories is growing, thus increasing the ability to use modern blood screening techniques. Although cost-related issues may be an issue, the region is rapidly embracing the use of new methods such as NAT and next-generation sequencing, especially in those countries that have better economic healthcare funding, to keep pace with the international blood safety standards.

KEY INDUSTRY PLAYERS

Key Players Transforming the Blood Screening Landscape through Innovation and Global Strategy

Technological innovation, especially in the fields of molecular diagnostics and automation, which is necessitated by the need to find higher precision, faster disease recognition, and reduced risks, is the main industrial factor that can affect this market. The constant development and implementation of technologies such as Nucleic Acid Testing (NAT), Next-Generation Sequencing (NGS) and automated screening platforms by large diagnostic firms are reshaping blood banking processes, facilitating earlier pathogen detection in the window period, and overall increasing the efficiency of the lab, along with the increased global demand for safe blood transfusion and the increase in the number of infectious diseases.

List Of Market Players Profiled

• Abbott Laboratories (U.S.)
• Abbott (U.S.)
• Apex Biotechnology Corp. (Taiwan)
• Beckman Coulter (A Subsidiary of Danaher Corporation) (U.S.)
• Becton, Dickinson and Company (U.S.)

INDUSTRIAL DEVELOPMENT

October 16, 2025: Grifols began production of Grifols DG Gel cards and reagent red blood cells (RRBCs) in its new plant in San Diego, U.S., on October 16, 2025, to meet the increased demand of blood typing solutions in the U.S.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis considers both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.